These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17128432)

  • 1. Herbal modulation of drug bioavailability: enhancement of rifampicin levels in plasma by herbal products and a flavonoid glycoside derived from Cuminum cyminum.
    Sachin BS; Sharma SC; Sethi S; Tasduq SA; Tikoo MK; Tikoo AK; Satti NK; Gupta BD; Suri KA; Johri RK; Qazi GN
    Phytother Res; 2007 Feb; 21(2):157-63. PubMed ID: 17128432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction of some antitubercular drugs with caraway: implications in the enhancement of drug bioavailability.
    Sachin BS; Monica P; Sharma SC; Satti NK; Tikoo MK; Tikoo AK; Suri KA; Gupta BD; Johri RK
    Hum Exp Toxicol; 2009 Apr; 28(4):175-84. PubMed ID: 19734267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuminum cyminum extract attenuates scopolamine-induced memory loss and stress-induced urinary biochemical changes in rats: a noninvasive biochemical approach.
    Koppula S; Choi DK
    Pharm Biol; 2011 Jul; 49(7):702-8. PubMed ID: 21639683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flavonoid glucosides from the hairy roots of Catharanthus roseus.
    Chung IM; Ahmad A; Ali M; Lee OK; Kim MY; Kim JH; Yoon DY; Peebles CA; San KY
    J Nat Prod; 2009 Apr; 72(4):613-20. PubMed ID: 19271765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of a standardised screening protocol for the in vivo assessment of rifampicin bioavailability.
    McIlleron H; Gabriels G; Smith PJ; Fourie PB; Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S329-35; discussion S351-2. PubMed ID: 10593713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of osteoclast differentiation from Cephalotaxus koreana.
    Yoon KD; Jeong DG; Hwang YH; Ryu JM; Kim J
    J Nat Prod; 2007 Dec; 70(12):2029-32. PubMed ID: 17994703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis.
    Nyazema NZ; Rabvukwa P; Gumbo J; Ndudzo P; Chitemerere C
    Cent Afr J Med; 1999 Jun; 45(6):141-4. PubMed ID: 10695183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety.
    Singh H; Jindal S; Singh M; Sharma G; Kaur IP
    Int J Pharm; 2015 May; 485(1-2):138-51. PubMed ID: 25769294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of subinhibitory concentrations of cumin (Cuminum cyminum L.) seed essential oil and alcoholic extract on the morphology, capsule expression and urease activity of Klebsiella pneumoniae.
    Derakhshan S; Sattari M; Bigdeli M
    Int J Antimicrob Agents; 2008 Nov; 32(5):432-6. PubMed ID: 18715764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
    Agrawal S; Panchagnula R
    Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Moringa oleifera on pharmacokinetic disposition of rifampicin using HPLC-PDA method: a pre-clinical study.
    Pal A; Bawankule DU; Darokar MP; Gupta SC; Arya JS; Shanker K; Gupta MM; Yadav NP; Singh Khanuja SP
    Biomed Chromatogr; 2011 Jun; 25(6):641-5. PubMed ID: 20845375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
    Ellard GA
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations.
    Ashokraj Y; Singh I; Kaur KJ; Kohli G; Bhade SR; Varma MV; Kaul CL; Panchagnula R
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):697-9. PubMed ID: 15971401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methanolic extract of Cuminum cyminum inhibits ovariectomy-induced bone loss in rats.
    Shirke SS; Jadhav SR; Jagtap AG
    Exp Biol Med (Maywood); 2008 Nov; 233(11):1403-10. PubMed ID: 18824723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bioavailability of two brands of rifampicin.
    Rewari S; Rath R; Gupta U
    J Assoc Physicians India; 1998 Aug; 46(8):751. PubMed ID: 11229300
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.
    Singh S; Mariappan TT; Bhutani H
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):701-2. PubMed ID: 15971403
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality assurance: protocol for assessing the rifampicin bioavailability of combined formulations in healthy volunteers.
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S284-5. PubMed ID: 10593705
    [No Abstract]   [Full Text] [Related]  

  • 19. Stimulatory effects of Cuminum cyminum and flavonoid glycoside on Cyclosporine-A and restraint stress induced immune-suppression in Swiss albino mice.
    Chauhan PS; Satti NK; Suri KA; Amina M; Bani S
    Chem Biol Interact; 2010 Apr; 185(1):66-72. PubMed ID: 20156427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin.
    Doan TV; Grégoire N; Lamarche I; Gobin P; Marchand S; Couet W; Olivier JC
    Eur J Pharm Sci; 2013 Jan; 48(1-2):223-30. PubMed ID: 23159665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.